ADDEX N revenue for the last year amounted to 1.60 M CHF, the most of which — 1.65 M CHF — came from its highest performing source at the moment, Small-molecule Pharmaceutical Products, the year earlier bringing 1.44 M CHF. The greatest contribution to the revenue figure was made by Switzerland — last year it brought ADDEX N 1.65 M CHF, and the year before that — 1.44 M CHF.